Anticoagulation in COVID pneumonia (ATTACC)

Principal Investigator(s):

Ryan Zarychanski, Alexis Turgeon, Patrick Lawler, Ewan Goligher

Status: Enrolment Complete

In noncritically ill patients with Covid-19, an initial strategy of therapeutic-dose anticoagulation with heparin increased the probability of survival to hospital discharge with reduced use of cardiovascular or respiratory organ support as compared with usual-care thromboprophylaxis.

View this trial on clinicaltrials.gov

View publications:

Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19 (2021)

Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19 (2021)

Therapeutic Anticoagulation in Critically Ill Patients with Covid-19 – Preliminary Report (2021)

Therapeutic Anticoagulation in Non-Critically Ill Patients with Covid-19 (2021)

Effects of inflammation on thrombosis and outcomes in COVID-19: secondary analysis of the ATTACC/ACTIV-4a trial (2023)

Heterogeneous Treatment Effects of Therapeutic-Dose Heparin in Patients Hospitalized for COVID-19 (2023)